PDF(Pubmed)
Abstract：
Inflammatory bowel disease (IBD) is a chronic, non-specific inflammatory condition characterized by recurring inflammation of the intestinal mucosa. However, the existing IBD treatments are ineffective and have serious side effects. The etiology of IBD is multifactorial and encompasses immune, genetic, environmental, dietary, and microbial factors. The nanoparticles (NPs) developed based on specific targeting methodologies exhibit great potential as nanotechnology advances. Nanoparticles are defined as particles between 1 and 100 nm in size. Depending on their size and surface functionality, NPs exhibit different properties. A variety of nanoparticle types have been employed as drug carriers for the treatment of inflammatory bowel disease (IBD), with encouraging outcomes observed in experimental models. They increase the bioavailability of drugs and enable targeted drug delivery, promoting localized treatment and thus enhancing efficacy. Nevertheless, numerous challenges persist in the translation from nanomedicine to clinical application, including enhanced formulations and preparation techniques, enhanced drug safety profiles, and so forth. In the future, it will be necessary for scientists and clinicians to collaborate in order to study disease mechanisms, develop new drug delivery strategies, and screen new nanomedicines. Nevertheless, numerous challenges persist in the translation from nanomedicine to clinical application, including enhanced formulations and preparation techniques, enhanced drug safety profiles, and so forth. In the future, it will be necessary for scientists and clinicians to collaborate in order to study disease mechanisms, develop new drug delivery strategies, and screen new nanomedicines.
摘要：
炎症性肠病(IBD)是一种慢性,以肠粘膜反复发炎为特征的非特异性炎症。然而,现有的IBD治疗无效且具有严重的副作用。IBD的病因是多因素的，包括免疫，遗传,环境,饮食，和微生物因素。随着纳米技术的发展，基于特定靶向方法开发的纳米颗粒（NP）显示出巨大的潜力。纳米颗粒被定义为尺寸在1和100nm之间的颗粒。根据它们的尺寸和表面功能，NP表现出不同的性质。多种纳米颗粒类型已被用作治疗炎症性肠病(IBD)的药物载体。在实验模型中观察到令人鼓舞的结果。它们增加了药物的生物利用度，并实现了靶向药物递送，促进局部治疗，从而提高疗效。然而，从纳米医学到临床应用的转化仍然存在许多挑战，包括增强的配方和制备技术，增强药物安全性，等等。在未来,科学家和临床医生有必要合作研究疾病机制，开发新的药物输送策略，筛选新的纳米药物。然而，从纳米医学到临床应用的转化仍然存在许多挑战，包括增强的配方和制备技术，增强药物安全性，等等。在未来,科学家和临床医生有必要合作研究疾病机制，开发新的药物输送策略，筛选新的纳米药物。
